Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyCapital Bluecross Blenrep Coverage Prior Auth | Op…
    Ask Trek AI about this page
    CurrentCapital BluecrossPolicy IC-0561

    Blenrep® (belantamab mafodotin-blmf)

    Customize your policy alerts

    Sign up for Capital Bluecross Policy IC-0561 alerts

    Get alerted when Policy IC-0561 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage stance for the intravenous oncology drug Blenrep for members of Capital Bluecross; it applies to requests for Blenrep and outlines medical necessity and billing information.

    Policy Summary
    PayerCapital Bluecross
    PolicyBlenrep® (belantamab mafodotin-blmf)
    Policy CodePolicy IC-0561
    Change TypeNo material change
    Effective DateSep 1, 2020
    Last ReviewNov 1, 2024
    Next Review DateNov 1, 2024
    Key ActionPrior Authorization is needed for Blenrep.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    not medically necessarycoverage stance
    prior authauthorization
    J9037HCPCS
    withdrawn 02/06/2023regulatory status
    RRMM ≥4 priororiginal indication

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage and Medical Necessity

    Medical Necessity Criteria

    Coverage determination for Blenrep

    Blenrep (belantamab mafodotin-blmf) is considered not medically necessary for all indications.

    Initial / Original Indication

    Initial/Original Indication

    Original indication and trial outcomes informing policy

    ALL of the following

    • Indication: adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
    • Regulatory event: FDA requested withdrawal of U.S. marketing authorization following failure to confirm clinical benefit in the Phase 3 DREAMM-3 trial; accelerated approval was officially withdrawn on February 6, 2023.

    Continuation Therapy

    Continuation Therapy

    Continuation may be allowed under limited circumstances

    Continuation of therapy may be considered only if the patient was previously enrolled in the Blenrep REMS program and chooses to enroll in the compassionate use program (REMS enrollment and compassionate use participation required).

    Provider Actions and Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Blenrep; submit a prior authorization request per Capital Bluecross policy before initiating therapy.

    Documentation Required

    Continuation / Compassionate Use Exception

    Continuation of Blenrep may be considered only for patients previously enrolled in the Blenrep REMS program who elect enrollment in the compassionate use program; document prior REMS enrollment and compassionate use participation.

    • Patient previously enrolled in Blenrep REMS
    • Patient chooses enrollment in the compassionate use program

    Billing Codes

    HCPCSHCPCSCovered
    J9037Injection, belantamab mafodontin-blmf, 0.5 mg; 1 billable unit = 0.5 mg
    NDCNDC
    00173-0896-xxBlenrep 100 mg lyophilized powder in single-dose vial for injection

    Regulatory Notes and Definitions

    Withdrawn accelerated approval — Blenrep (belantamab mafodotin-blmf)
    DefinitionAccelerated approval withdrawal: The FDA requested withdrawal of Blenrep's U.S. marketing authorization after the Phase 3 DREAMM-3 trial failed to confirm required clinical benefit.
    Regulatory action dateOfficially withdrawn on February 6, 2023.
    Reason for withdrawalDREAMM-3 failed to meet its primary endpoint of progression-free survival versus pomalidomide plus low‑dose dexamethasone; data were insufficient to confirm clinical benefit.
    Original accelerated approval basisAccelerated approval (August 2020) was based on overall response rate (ORR) and duration of response (DOR) data from the Phase 2 DREAMM-2 trial.
    Trial specifics citedDREAMM-3 randomized 325 patients 2:1 to Blenrep 2.5 mg/kg every 3 weeks versus PomDex; median PFS 11.2 months (Blenrep) vs 7 months (PomDex) but hazard ratio 1.03 (95% CI 0.72–1.47), not demonstrating benefit.
    Policy Summary
    PayerCapital Bluecross
    PolicyBlenrep® (belantamab mafodotin-blmf)
    Policy CodePolicy IC-0561
    Change TypeNo material change
    Effective DateSep 1, 2020
    Last ReviewNov 1, 2024
    Next Review DateNov 1, 2024
    Key ActionPrior Authorization is needed for Blenrep.
    SourceLink
    On This Page
    Coverage and Medical NecessityInitial / Original IndicationContinuation TherapyProvider Actions and AuthorizationBilling CodesRegulatory Notes and Definitions